Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 318-331
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.318
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.318
Figure 1 Evaluation of the tissue expression and diagnostic utility of microRNA-627 in the GSE41655 and GSE18392 datasets.
A: Tissue expression of microRNA-627 (miR-627) in the healthy controls (HCs) and colorectal cancer (CRC) patients in the GSE41655 dataset; B: Tissue expression of miR-627 in the HCs and CRC patients in the GSE18392 dataset; C: Receiver operating characteristic analysis of miR-627 to distinguish CRC patients from HCs in the GSE41655 dataset; D: Receiver operating characteristic analysis of miR-627 to distinguish CRC patients from HCs in the GSE18392 dataset. HCs: Healthy controls; CRC: Colorectal cancer. bP < 0.01; cP < 0.001.
- Citation: Zhao DY, Yin TF, Sun XZ, Zhou YC, Wang QQ, Zhou GY, Yao SK. microRNA-627-5p inhibits colorectal cancer cell proliferation, migration and invasion by targeting Wnt2. World J Gastrointest Oncol 2023; 15(2): 318-331
- URL: https://www.wjgnet.com/1948-5204/full/v15/i2/318.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i2.318